The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.
CONCLUSION: Rituximab induced remission in all patients with corticosteroid-dependent or -resistant minimal-change glomerulopathy, and may hold great therapeutic potential with good efficacy and minimal toxicity. Mounting evidence implies that a well-conducted randomized controlled clinical trial using rituximab in adults with minimal-change glomerulopathy in both corticosteroid-resistant and corticosteroid-dependent patients is warranted.
PMID: 28315862 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Brown LC, Jobson MA, Payan Schober F, Chang EH, Falk RJ, Nachman PH, Pendergraft WF Tags: Am J Nephrol Source Type: research
More News: Children | Clinical Trials | Corticosteroid Therapy | Glomeruli | Rituxan | Toxicology | Urology & Nephrology